HomeCompareWINSF vs JNJ

WINSF vs JNJ: Dividend Comparison 2026

WINSF yields 200000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WINSF wins by $4.911780474428384e+29M in total portfolio value
10 years
WINSF
WINSF
● Live price
200000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.911780474428384e+29M
Annual income
$490,695,411,370,591,700,000,000,000,000,000,000.00
Full WINSF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — WINSF vs JNJ

📍 WINSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWINSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WINSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WINSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WINSF
Annual income on $10K today (after 15% tax)
$17,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$417,091,099,665,002,940,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, WINSF beats the other by $417,091,099,665,002,940,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WINSF + JNJ for your $10,000?

WINSF: 50%JNJ: 50%
100% JNJ50/50100% WINSF
Portfolio after 10yr
$2.455890237214192e+29M
Annual income
$245,347,705,685,295,860,000,000,000,000,000,000.00/yr
Blended yield
99.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

WINSF
No analyst data
Altman Z
-5.2
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WINSF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWINSFJNJ
Forward yield200000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.911780474428384e+29M$30.3K
Annual income after 10y$490,695,411,370,591,700,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.911464459982279e+29M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WINSF vs JNJ ($10,000, DRIP)

YearWINSF PortfolioWINSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,010,700$20,000,000.00$10,592$272.30+$20.00MWINSF
2$37,424,589,019$37,403,177,570.09$11,289$357.73+$37424.58MWINSF
3$65,416,215,188,220$65,376,170,877,969.18$12,123$472.89+$65416215.18MWINSF
4$106,868,230,495,008,900$106,798,235,144,757,520.00$13,141$629.86+$106868230495.00MWINSF
5$163,172,871,735,896,870,000$163,058,522,729,267,200,000.00$14,408$846.81+$163172871735896.88MWINSF
6$232,854,599,801,468,860,000,000$232,680,004,828,711,460,000,000.00$16,021$1,151.60+$232854599801468864.00MWINSF
7$310,570,858,137,017,100,000,000,000$310,321,703,715,229,540,000,000,000.00$18,122$1,588.22+$310570858137017057280.00MWINSF
8$387,148,154,301,613,200,000,000,000,000$386,815,843,483,406,600,000,000,000,000.00$20,930$2,228.20+$3.871481543016132e+23MWINSF
9$451,061,749,763,281,040,000,000,000,000,000$450,647,501,238,178,360,000,000,000,000,000.00$24,792$3,191.91+$4.510617497632811e+26MWINSF
10$491,178,047,442,838,440,000,000,000,000,000,000$490,695,411,370,591,700,000,000,000,000,000,000.00$30,274$4,689.40+$4.911780474428384e+29MWINSF

WINSF vs JNJ: Complete Analysis 2026

WINSFStock

Wins Finance Holdings Inc., through its subsidiaries, provides financial leasing and advisory services for small and medium enterprises in the People's Republic of China. The company offers direct equipment leasing or purchase-lease-back services; and financial advisory services. Wins Finance Holdings Inc. is headquartered in Beijing, the People's Republic of China.

Full WINSF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this WINSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WINSF vs SCHDWINSF vs JEPIWINSF vs OWINSF vs KOWINSF vs MAINWINSF vs ABBVWINSF vs MRKWINSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.